Multiple Myeloma; ENDEAVOR Trial

The panelists, Keith Stewart, MB, CHB; Jatin J. Shah, MD; Paul G. Richardson, MD; Ajai Chari, MD; and Sagar Lonial, MD, examine the significance of the ENDEAVOR trial, which compared carfilzomib and dexamethasone versus bortezomib and dexamethasone in individuals with relapsed or refractory multiple myeloma.